Please assess the completion status of the following clinical trial:

Trial Title: Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have histologically confirmed primary melanoma of Breslow thickness 1.0-4.0 mm; patients who have had only their initial biopsy are preferred; however, those who have already undergone a wide local excision are also eligible; patients may be enrolled up to three months after their wide local excision~* Patients whose melanoma is \> 4.0 mm thick who have positive or negative regional lymph nodes are also eligible~* After accrual to the original 26 patient goal, all patients must be enrolled prior to sentinel lymph node dissection; patients with previous lymph node dissection will not be eligible~* Patients must be HLA typed and be shown to be HLA-A2.1+ by either serologic techniques, flow cytometry, or molecular techniques~* Patients must be ambulatory with good performance status (Karnofsky performance status \[PS\] 80-100)~* White blood cell (WBC) \>= 3500/mm\^3~* Platelets (Plt) \>= 100,000/mm\^3~* Hemoglobin \>= 9 gm/100 ml~* Serum creatinine =\< 2 mg/dl~* Total bilirubin =\< 2.0 mg/dl~* Patients must have recovered from any effects of major surgery and be free of significant systemic infection~* Patients must be negative for human immunodeficiency virus (HIV) antibody by enzyme-linked immunosorbent assay (ELISA) (or negative by Western blot if ELISA is positive) if they are considered to be at high risk; others do not require serologic testing if there are no symptoms or risk factors for HIV disease~* Women of childbearing potential must have a negative pregnancy test and should avoid becoming pregnant while on treatment~* Patients must give written informed consent prior to initiation of therapy; patients with a history of major psychiatric illness must be judged able to fully understand the investigational nature of the study and the risks associated with the therapy~Exclusion Criteria:~* Patients must not have clinically detectable distant metastases~* Patients who require or are likely to require systemic corticosteroids for intercurrent illness~* Patients with any significant medical disease other than the malignancy (e.g. chronic obstructive pulmonary disorder \[COPD\], patients with ascites or pleural effusions) which in the opinion of the investigator would significantly increase the risk of immunotherapy~* Patient should be free of any other cancers or deemed at low risk for their recurrence

- Gender: ALL
- Minimum Age: 17 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- gp100:209-217(210M) + HPV 16 E7:12-20 (every 2 weeks) (Type: EXPERIMENTAL): Patients receive gp100:209-217(210M) peptide vaccine and HPV 16 E7:12-20 peptide vaccine mixed with incomplete Freund's adjuvant SC every 2 weeks for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo laboratory biomarker analysis.
- gp100:209-217(210M) + HPV 16 E7:12-20 (every 3 weeks) (Type: EXPERIMENTAL): Patients receive gp100:209-217(210M) peptide vaccine and HPV 16 E7:12-20 peptide vaccine mixed with incomplete Freund's adjuvant SC every 3 weeks for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo laboratory biomarker analysis.

Based on this trial design, predict the completion outcome and termination type (if applicable).